Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics
GET POWR RATINGS... FREE!
MIST Stock Price Chart Interactive Chart >
MIST Price/Volume Stats
| Current price | $5.57 | 52-week high | $9.03 |
| Prev. close | $5.65 | 52-week low | $5.09 |
| Day low | $5.54 | Volume | 3,618 |
| Day high | $5.65 | Avg. volume | 67,518 |
| 50-day MA | $5.67 | Dividend yield | N/A |
| 200-day MA | $6.25 | Market Cap | 166.24M |
Milestone Pharmaceuticals Inc. (MIST) Company Bio
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Latest MIST News From Around the Web
Below are the latest news stories about Milestone Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIST as an investment opportunity.
Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare ConferenceMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 10:00 a.m. ET. The conference will be held in a virtual meeting format. |
Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021. |
What Kind Of Shareholders Own Milestone Pharmaceuticals Inc. (NASDAQ:MIST)?If you want to know who really controls Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ), then you'll have to look at the... |
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate UpdateMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update. |
10 Stocks to Buy According to Neil Shahrestani’s Ikarian CapitalIn this article, we will take a look at the 10 stocks to buy according to Neil Shahrestani’s Ikarian Capital. To skip our detailed analysis of Shahrestani’s history, hedge fund performance, and investment philosophy, go directly to the 5 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital. Neil Shahrestani, MD, is the Chief Investment Officer, managing […] |
MIST Price Returns
| 1-mo | -11.45% |
| 3-mo | 1.27% |
| 6-mo | -7.93% |
| 1-year | -25.83% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.87% |
| 2020 | -58.15% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...